Biocept Inc. ($BIOC) recently released its third-quarter results, which showed that revenue had quadrupled year-over-year (revenues of $6.6 million). This was explained by analysts on the basis of a strategically strong move by offering a molecular diagnostics to test the coronavirus (RT-PCR test).

Offering COVID-19 testing services has been the right choice and is expected to be an important part for Biocept as long as the pandemic is not fully under control. In addition, oncology remains on the agenda for a long-term focus, with the belief that the company wants to continue to develop and expand in a post-pandemic future.

The Biocept Target Selector Study

The Biocept Target Selector Study – a high-potential study that monitors tumor progression – will be presented at a major breast cancer conference on December 9, 2020. It concerns one in a poster presentation at the virtual San Antonio Breast Cancer Symposium (SABCS).

More specifically, the study monitors expression of the protein HER2 over time, providing a window on tumor progression. HER2 expression in matched metastatic tumor and circulating tumor cells (CTCs) in breast cancer: implications for HER2 status profiling and monitoring to help guide anti-HER2 therapy. About 20% of breast cancers test positive for the HER2 protein and during treatment and with disease progression, the HER2 receptor can be converted from positive to negative. It is important that more research is done on this, as one in eight women in the United States still develops breast cancer, despite the rapid and better early detection of breast cancer.

The problem is that once breast cancer has spread, it is difficult to access multiple metastatic sites or perform serial tissue biopsies to determine if HER2 conversion has occurred. This prospective study was designed to evaluate the use of liquid biopsy in comparison to tissue biopsy for analysis of HER2 status over time.

Biocept believes its tumor-detecting Target Selector platform can make a big difference to patients. The ability to monitor changes in tumor changes can provide clinicians with crucial information in reassessing options while treating patients with metastatic breast cancer.

Neither PSN nor its owners, members, officers, directors, partners, consultants, nor anyone involved in the publication of this website, is a registered investment adviser or broker-dealer or associated person with a registered investment adviser or broker-dealer and none of the foregoing make any recommendation that the purchase or sale of securities of any company profiled in the PSN website is suitable or advisable for any person or that an investment or transaction in such securities will be profitable. The information contained in the PSN website is not intended to be, and shall not constitute, an offer to sell nor the solicitation of any offer to buy any security. The information presented in the PSN website is provided for informational purposes only and is not to be treated as advice or a recommendation to make any specific investment. Please consult with an independent investment adviser and qualified investment professional before making an investment decision.